Mary Beth Dorr

Title: Mary Beth Dorr: Innovator in Genetic Markers for Clostridium Difficile Treatment

Introduction

Mary Beth Dorr is a notable inventor based in Collegeville, PA (US). She has made significant contributions to the field of genetics, particularly in identifying human genetic markers associated with responses to treatments targeting clostridium difficile toxin B. Her work has the potential to improve patient outcomes in treating diseases susceptible to this toxin.

Latest Patents

Mary Beth Dorr holds a patent for her invention titled "Human genetic markers associated with response to treatments that target clostridium difficile toxin B." This patent provides valuable genetic markers located on human chromosome 6 that are linked to beneficial responses to treatments targeting toxin B, such as TcdB antibodies. These markers are instrumental in identifying patients who are likely to benefit from such treatments, thereby aiding in selecting the most appropriate therapy. The invention also encompasses antibodies, drug products, and kits that utilize these TcdB treatment response markers.

Career Highlights

Throughout her career, Mary Beth Dorr has worked with prominent organizations, including Merck Sharp & Dohme Corporation and the Beijing Genomics Institute at Shenzhen. Her experience in these institutions has allowed her to contribute to groundbreaking research and development in the field of genetics and therapeutics.

Collaborations

Mary Beth has collaborated with esteemed colleagues such as Peter M Shaw and Devan V Mehrotra. These partnerships have further enriched her research and innovation efforts.

Conclusion

Mary Beth Dorr's work in identifying genetic markers for clostridium difficile treatment represents a significant advancement in medical science. Her contributions have the potential to enhance treatment strategies and improve patient care.